### Principles of Clinical Pharmacology

Module 2: Drug Metabolism and Transport

Unit 6: Concentrative and Equilibrative Drug Transport

Peter C. Preusch, Ph.D. Pharmacology, Physiology, and Biological Chemistry Division National Institute of General Medical Sciences

### Objectives

- Vision, reality, and the path between.
- Methods of measuring drug transport *in vitro* and *in vivo*.
- Mechanisms of drug transport.
- Recent advances in understanding the role of membrane transport proteins.
- Clinical significance.


### Measurement of Drug Distribution/Transport In Vivo


- Tissue Samples, Biopsies, and Assays
- Autoradiography
- Perfusion/Cannulation Methods
- Radiology x-ray, PET, SPECT
- Magnetic Resonance Imaging
- Microdialysis


# Measurement of Transport In Vitro


- Ussing chamber transport across tissue samples high level of control
- Everted gut sac uptake from medium
- Uptake/Efflux by cells in culture (CHO)
- Confocal microscopy of cultured cells

   fluorescent drugs (mitoxantrone, rhodamine)
- Monolayer cell cultures
  - Caco-2 cells, MDKII, brain microvascular endothelial










### Thermodynamics of Transport

- Transport of neutral species
- Ions & transmembrane potentials
- Ionizable species & proton gradients
- Metals and other titrants
- Macromolecular and cellular binding sites
- Coupled transport and ATP driven pumps
- Chemical conversions



# Equations for Membrane Transport Thermodynamics

```
\mathbf{D}\mathbf{G}_{transp} = 2.303 \text{RT} \log[\mathbf{S}_i]/[\mathbf{S}_o] + nF\mathbf{D}\mathbf{Y} + \mathbf{D}\mathbf{G}_{pump}
```

```
\label{eq:kappa} \begin{split} R &= 8.314 \; joules/mol^\circ K = 1.987 \; cal/mol^\circ K \\ F &= 96.5 \; Joules/mol-mV = 23.06 \; cal/mol-mV \end{split}
```

#### $D[S_i]/[S_o] = 10x @ 296^{\circ}K (23^{\circ}C) 310^{\circ}K (37^{\circ}C)$

$\Delta(\Delta G) =$	=
-	=
$\Delta(\Delta \Psi) =$	=

 5.67 kJ/mol
 5.936 kJ/mol

 1.35 kcal/mol
 1.41 kcal/mol

 58.5 mV
 61.5 mV

pH = pKa + log[S]/[SH]

# Examples Mechanism/Drug/Compartment

Diffusion Ion trapping pH trapping Binding Active antipyrene Tc-Sestamibi quinidine warfarin captopril

total body water heart mitochondria renal excretion plasma/liver ratio GI absorption


### Drug Metabolism & Transport Peter C. Preusch, Ph.D.

### Passive Diffusion

- Characteristics of passive diffusion
  - $\mathbf{k}_{in} = \mathbf{k}_{out}$ , net rate = k([S<sub>o</sub>] [S<sub>i</sub>]), non-selective
- Model Membranes
   monolayers, bilayers, liposomes, BLMs, IAMs
- Membrane Models

   structural, electrical, single/multiple barrier, partition adsorption/diffusive, unstirred layers
- Simulation of bilayers and transport – molecular dynamics
- QSAR structure/transport correlations

### Molecular Dynamics Simulation of Membrane Diffusion



From: Bassolino-Klimas, Alper and Stouch, ref. 16. See also ref. 17.

Snapshot from 10 nsec MD simulation in 100 fs steps. Showed hopping motions of 8 Å over ca 5 psec vs RMS motions of 1.5 Å. Motions differ in center and near surface, both differ from bulk organic. Rotational isomerizations (gauche/trans) gate channels between voids. Differing motions available to adamantane, nifedipine.

# QSAR of Transport

#### • Hansch Equation

- $\ log \ (1/C) = -k(log P)^2 + k'(log P) + \rho\sigma + \ k''$
- $C = dose \text{ or } [S] \text{ for effect } (ED_{50}, IC_{50}, rate)$
- $-\log P = partition coef or \pi = lipophilicity factor$
- $\label{eq:static} \begin{array}{l} \ \sigma = Hammett \ electronic \ substituent \ effects \\ \ k, \ k', \ k'', \ \rho = regression \ coefficients \end{array}$
- $-\kappa, \kappa', \kappa'', \rho = regression co$
- Free-Wilson Model
   BA = ΣajXj + μ
  - $BA = 2a_JA_J + \mu$ - BA = biological activity (e.g., log(1/c))
  - aj = substuent constant, Xj = substituent presence,
  - $\mu$  = overall average activity

#### **QSAR** of Transport Selected from: V.Austel & E. Kutter in Ref. 18. ABSORPTION - log (%abs), log Perm, log k Barbiturates Gastric log P<sub>CHCL3/W</sub> log P<sub>isoam-OAC/w</sub> Sulfonamides Gastric Anilines Gastric pKa Distribution Coef Xanthines Intestine C-glycosides log P<sub>o/w</sub>, R<sub>m</sub> Intestine Excretion - log (% excreted), log $Cl_{R}$ , log k logP, R<sub>m</sub> Penicillins Biliary Suflathiazoles Biliary logP<sub>o/w</sub>, pKa Rm, pKa Sufapyridines Renal Sulfonamides Renal π, pKa Amphetamines Renal logP<sub>h/w</sub>

# QSAR Conclusions

- Lipophilicity (logP<sub>o/w</sub>); CLOGP
- GI (0.5-2.0), buccal (4-4.5), topical (>2.0)
- Water solubility
- melting point, solvation energy
- pKa fraction of neutral species available
- mw D  $\propto 1/\sqrt{mw}$ ; mw < 500 Da
- Confounding factors
  - inaccurate data, multiple mechanisms

### Mediated Transport: Facilitated Diffusion and Active Transport

- Rates > passive, solute specific, high Q<sub>10</sub>
- Non-symmetrical  $(k_{in} \neq k_{out} \text{ at } [S_i] = [S_o])$
- Saturable transport Michaelis-Menten
- Inhibitable competitive, non-competitive
- Regulated inducibility & repression
- Tissue specific- differential expression
- Energy dependent active transport
  - primary pumps respiration, photosyn, ATPase
  - secondary transporters (coupled to  $H^+$ ,  $Na^+$  etc.)

### Mechanisms of Transport and Example Drugs (in Bacteria) Adapted from: R.E. Hancock, p. 292, in Ref. 15.

- Passive diffusion across lipid bilayer
  fluoroquinolones, tetracycline (hydrophobic\_
- Diffusion through OM channels and porins
   B-lactams (hydrophilic and charged)
- Facilitated diffusion
  - imipenem, catechols, albomycin, albicin
- Active Transport
  - aminoglycosides, cycloserine, phosphomycin, alaphosphin


# Pinocytosis, Endocytosis, and Receptor Mediated Transcytosis

- Pinocytosis (cell sipping non-mediated)

   non-specific, non-saturable, bulk fluid phase uptake, large particles, polymer-conjugates, obsolete term?
- Endocytosis (receptor-mediated uptake)

   specific, relevant to macromolecules, used to deliver small molecules as prodrugs, mediates clearance
   insulin, growth hormone, erythropoetin, G-CSR, ILs
- Transcytosis (receptor-mediated uptake and secretion on the translateral surface)

   useful for macromolecules and small molecule prodrugs, GI, BBB, and pulmonary epithelia.



# Cell Culture and Molecular Biology Methods

- Isolation of MXR genes (Ref. 25).
  - Cells cultured from patients w/ resistant tumors.
  - mitoxantrone uptake measured microscopically
  - Cells grown under progressively selective conditions mitoxantrone, adriamycin, verapamil
  - Isolation of differentially expressed mRNA as cDNA clones and cDNA sequencing.
  - Northern analysis of mRNA expression levels.
  - Southern analysis of gene copy amplification.
  - Quantitative PCR analysis of expression levels
  - in non-selected resistant cells.

# Cell Culture and Molecular Biology Methods (Cont'd).

- Isolation of BCRP genes (Ref. 26-27)
  - cells same as from Ref. 25
  - cultured under selective conditions w/ doxorubicin and verapamil
  - RNA fingerprinting used to isolate cDNAs.
  - transfection of non-selected cells confers resistance to mitoxantrone, doxorubicin, daunorubicin
  - reduced uptake (dauno), enhance efflux
  - (rhodamine 123)
  - Northern/Southern analysis of various cell lines

# Cell Culture and Molecular Biology Methods (Cont'd II)

- Isolation of MOAT-B,C,D (Ref. 28)
  - cMOAT (cannicular multispecific organic anion transporter) = MRP previously isolated
  - MOAT-B isolated by PCR
  - Homology search against EST datase suggests MOAT-C & MOAT-D
  - EST probe isolation of cDNA from human
  - RNA blot analysis of tissue expression library
  - chromosomal location by FISH

# Cell Culture and Molecular Biology Methods (Cont'd III)

- · Other Cloning Methods
  - Expression cloning in oocytes
  - Homologous hybridization
  - Cloning by RT-PCR with degenerate primers
  - Cloning by functional complementation

### Cell Culture and Molecular Biology Methods (Cont'd IV).

- What have you got? MXR, BCRP, MDR, MRP, ABC
  - Homology search against database BLAST
  - Hydropathy analysis Kyte-Dolitte
  - Sequence alignments and motifs
  - Homology modeling
  - Sequences of suggestive of transporter family

### **Biochemistry and Biophysics**

- Functional characterization
  - Expression of Transport Activity in Vitro
  - Substrate structure/activity profiles and cosubstrates (GSH, ATP, H+, Na+), uncouplers
  - Tissue distribution EST database, RNA expression levels, antibodies, in situ methods
  - Phenotypes in Knock Out Rodents
  - Subcellular localization microscopy
  - Isolation, purification, reconstitution
  - Structural biology EM, X-ray, NMR
  - Mechanism of substrate transport and energy
  - coupling enzymology, inhibition, drug design

### Membrane Transporter Families ABC Superfamily Major Facilitator

ABC Superfamily ABC peptide transporter

family P-glycoprotein (MDR) family MDR1a,1b,2,3 - organic cations, lipids (PC) MRP1,2,3 - organic anions, GSX conjugates cMOAT - canalicular

multispecific organic anion

transporter = MRP2?

transport

cBAT - canalicular bile acid

### POT - proton coupled oligopeptide transporter NT - Na+ coupled nucleotide transporter NTCP - N+ coupled taurocholate protein OATP - polyspecific organic anion transport protein OAT-K1 - renal methotrexate transporter OCT - organic cation transporter - electrogenic RFC - reduced folate carrier sGSHT - glutathione conjugate

Superfamily

transporter

Nucleotide Transporters of Mammalian Cells es ei N1/cit N2/cit N4/cit N3/cib N5/cs out out data data data data data data in Ado Ado Ado Ado Ado Ado Ado Urd Urd Urd Urd Urd Urd Urd Of dThd dThd Guo dThd dThd ThB Guo Guo FB Tub Tub From: C.E. Cass, in Ref. 31, Fig. 3, p. 413.

Nucleoside Drug Transporters Adapted from:C.E. Cass (Tables 1-4) in Ref 31.		
Cladribine (Cl-dAdo)	Leukemia	es, ei, N1, N5
Cytarabine (araC)	Leukemia	es, ei
2-Fludarabine (F-araA)	Leukemia	es, N1, N5
Pentostatin (dCF)	Leukemia	es
Floxidine (F-dUrd)	Colon Cancer	es, ei
Didanosine (ddI)	HIV	es, NB
Zalcitabine (ddC)	HIV	es, N2
Zidovudine (AZT)	HIV	N2
Acyclovir (ACV)	HSV	NB
Gancyclovir (GCV)	HSV	es, NB
Vidarabine (araA)	HSV	es, ei, Nl
Idoxuridine (IdUrd)	HSV	es
Trifluridine (F3-dThd)	HSV	ND
Ribavirin (RBV)	RNA/DNA	ND

# Drug Adsorption, Distribution, Tissue Uptake, and Elimination

- Gastrointestinal absorption

   lumenal uptake into enterocyte (apical)
   release to blood stream (basolateral)
- Hepatic clearance
  - sinusoidal uptake into hepatocyte
  - secretion of metabolites into blood
  - secretion into bile canniculi
- Renal tubular secretion (and resorption)
  - uptake from blood stream (basolateral)
  - release to lumen (apical)


- Tissue uptake to site of action


  cell membrane uptake (and secretion)
  uptake into subcellular compartment


  Blood Brain Barrier


  uptake from blood stream into endothelial cell
  secretion into brain interstitial space


  Blood Cerebrospinal Eluid Barrier scheroid
- Blood Cerebrospinal Fluid Barrier choroid plexes
  - uptake from extravascular fluid into epithelium (basolateral)
  - release to ventricle (apical)














# Exploiting Nutrient Transporters to Enhance Drug Bioavailability (Ref. 43)

- Valacyclovir is an amino acid ester prodrug of the antiviral drug acyclovir.
- Oral biovailability (AUC) is increased in humans 3-5x.
- Intestinal permeability in a rat perfusion model is increased 3-10x. Effect is specific (SAR), stereospecific (L), saturable, and inhibitable by PEPT1 subsrates (cephalexin, dipeptides), and by gly-acyclovir, val-AZT.
- Competitive with <sup>3</sup>H-gly-sarc in CHO/hPEPT1 cells.
- Enhanced, saturable, inhibitable mucosal to serosal transport demonstrated in CACO-2 cells and accompanied by hydrolysis. Serosal to mucosal transport is passive.

### Drug Interactions & Drug Transport


- Digoxin cardiac glycoside, narrow therapeutic index, substrate for PgP
  - Verapamil Ca channel blocker co-therapy for arrythmia. Increases plasma digoxin [60-90%], reduces renal clearance, apparently through inhibition of tubular PgP (44).
  - St. John's wort (Hypericum perforatum) decreased digoxin AUC by 25% after 10 days treatment through induction of PgP (45).


### Drug Resistance Reversal Agents

- valspodar is a PgP modulator under development by Novartis Pharma AG (46).
  - Steady state digoxin therapy was established in normal healthy volunteers (1 mg then 0.125 mg/day). Initiation of valspodar (400 mg followed by 200 mg twice per day) caused immediate and progressive increases in digoxin AUC (+211%) and decreases in total body, renal, and non-renal clearance (-67%, -73%, -58%) after 5 days.

# Microbial Drug Transport and Resistance Mechanisms


- Mechanisms of Drug Uptake in Bacteria
  - OM porins, periplasmic binders, and IM pumps
  - B-lactam channels imipenem resistance
  - siderophore uptake is a drug delivery target
- Mechanisms of Drug Efflux in Bacteria
  - Major facilitatory (MF) family
  - RND family (AcrAB, EmrAB, TolC)
  - SMR (small multidrugresistance pumps)
  - ABC (ATP binding cassette) family





# Pharmacogenomics of Transport

- Bacterial, Protozoal, and Plant Genomes – classification of gene transporters families
- Human Genome
  - EST databases
  - complete genome mapping and sequencing
- Bioinformatics
  - Structural Genomics
- Functional Genomics
  - High throughput screening



### Pharmacogenetics of Transport

- Misappropriated as term used for genetics of bacterial drug resistance.
- Polymorphism detected in p-glycoprotein in normal versus drug selected cell lines.
- RFLP predicts ivermectin neurotoxicity sensitive P-gp-deficient mice.
- hCNT1 (SPNT) from kidney and hCNT2 (small intestine) are identical except R75S.